Druggability & Clinical Context
Druggability
Low
Score: 0.26
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
1
Approved:
0
In Clinical Trials:
0
Drug Pipeline (1 compounds)
1 Preclinical
Mechanism: Prioritized from 1 SciDEX hypotheses, including: Restoring Neuroprotective Tryptophan Metabolism via Targeted Probiotic Engineering
Drug Pipeline (1 compounds)
1 Preclinical
Known Drugs:CHEMBL3228258 (preclinical)
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Clinical Trials (3)
Relevant trials from ClinicalTrials.gov
By Phase
PHASE2: 1 · PHASE4: 2
PHASE4
NCT04986995
n=22
Parkinson Disease
Interventions: Opicapone
Sponsor: Bial - Portela C S.A. | Started: 2021-06-09
PHASE4
NCT04986982
n=144
Parkinson Disease
Interventions: Opicapone 50 mg, Placebo
Sponsor: Bial - Portela C S.A. | Started: 2021-02-25
PHASE2
NCT02680977
n=18
Parkinson's Disease
Interventions: MP-Equivalent, MP-Low, MP+DDCI
Sponsor: ASST Gaetano Pini-CTO | Started: 2016-02